{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Biological+Control&page=11",
    "query": {
      "intervention": "Biological Control",
      "page": 11
    },
    "page_size": 10
  },
  "pagination": {
    "page": 11,
    "page_size": 10,
    "total_count": 1572,
    "total_pages": 158,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Biological+Control&page=12&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Biological+Control&page=10&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-21T22:20:48.411Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06023576",
      "title": "A Study of Blood Pressure Control During Cancer Treatment",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "Cardiotoxicity"
      ],
      "interventions": [
        {
          "name": "antihypertensive medications",
          "type": "OTHER"
        },
        {
          "name": "Blood pressure measurement",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Echocardiogram",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Symptom-limited cardiopulmonary exercise test",
          "type": "OTHER"
        },
        {
          "name": "Quality of Life Measures",
          "type": "OTHER"
        },
        {
          "name": "Biomarkers",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 130,
      "start_date": "2023-08-18",
      "completion_date": "2029-05-30",
      "has_results": false,
      "last_update_posted_date": "2026-05-14",
      "last_synced_at": "2026-10-21T22:20:48.411Z",
      "location_count": 7,
      "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more",
      "locations": [
        {
          "city": "Basking Ridge",
          "state": "New Jersey"
        },
        {
          "city": "Middletown",
          "state": "New Jersey"
        },
        {
          "city": "Montvale",
          "state": "New Jersey"
        },
        {
          "city": "Commack",
          "state": "New York"
        },
        {
          "city": "Harrison",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06023576"
    },
    {
      "nct_id": "NCT02010203",
      "title": "A Phase 1/2 Study of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer After TURBT",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "HS-410",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BCG",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Heat Biologics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 104,
      "start_date": "2013-12",
      "completion_date": "2018-04",
      "has_results": true,
      "last_update_posted_date": "2020-02-17",
      "last_synced_at": "2026-10-21T22:20:48.411Z",
      "location_count": 19,
      "location_summary": "Los Angeles, California • Sherman Oaks, California • Torrance, California + 16 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sherman Oaks",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02010203"
    },
    {
      "nct_id": "NCT01181986",
      "title": "The Study of Exenatide Action on Vessel Function in Type 2 Diabetes and Prediabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Exenatide SC",
          "type": "DRUG"
        },
        {
          "name": "Exenatide IV",
          "type": "DRUG"
        },
        {
          "name": "Placebo SC",
          "type": "DRUG"
        },
        {
          "name": "Exendin-9",
          "type": "DRUG"
        },
        {
          "name": "Placebo IV",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Carl T. Hayden VA Medical Center",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "35 Years to 70 Years"
      },
      "enrollment_count": 76,
      "start_date": "2010-08",
      "completion_date": "2012-12",
      "has_results": true,
      "last_update_posted_date": "2014-05-20",
      "last_synced_at": "2026-10-21T22:20:48.411Z",
      "location_count": 1,
      "location_summary": "Phoenix, Arizona",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01181986"
    },
    {
      "nct_id": "NCT00845182",
      "title": "Effect of Pioglitazone and Exenatide on Body Weight and Beta Cell Function",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Type 2 Diabetes",
        "Healthy",
        "Impaired Glucose Tolerance"
      ],
      "interventions": [
        {
          "name": "Pioglitazone",
          "type": "DRUG"
        },
        {
          "name": "Exenatide",
          "type": "DRUG"
        },
        {
          "name": "Pioglitazone and Exenatide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The University of Texas Health Science Center at San Antonio",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 43,
      "start_date": "2007-06",
      "completion_date": "2010-07",
      "has_results": true,
      "last_update_posted_date": "2018-01-18",
      "last_synced_at": "2026-10-21T22:20:48.411Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00845182"
    },
    {
      "nct_id": "NCT03082573",
      "title": "Efficacy, Radiographic and Laboratory Changes in Refractory Rheumatoid Arthritis Patients Treated With H.P. Acthar Gel",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "H.P. Acthar gel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Iraj Sabahi Research Inc.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2017-03-03",
      "completion_date": "2019-02",
      "has_results": false,
      "last_update_posted_date": "2017-03-17",
      "last_synced_at": "2026-10-21T22:20:48.411Z",
      "location_count": 2,
      "location_summary": "Pleasanton, California • Turlock, California",
      "locations": [
        {
          "city": "Pleasanton",
          "state": "California"
        },
        {
          "city": "Turlock",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03082573"
    },
    {
      "nct_id": "NCT06874283",
      "title": "Ocular Complications From Cancer Therapy - Patient Registry and Biobank",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Graft Versus Host Disease in Eye",
        "Ocular Complications",
        "Inflammatory Dry Eye Disease"
      ],
      "interventions": [
        {
          "name": "Eye exam",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "University of Maryland, Baltimore",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 150,
      "start_date": "2025-05-13",
      "completion_date": "2031-04",
      "has_results": false,
      "last_update_posted_date": "2026-03-05",
      "last_synced_at": "2026-10-21T22:20:48.411Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06874283"
    },
    {
      "nct_id": "NCT02650986",
      "title": "Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Fallopian Tube Carcinoma",
        "Advanced Malignant Solid Neoplasm",
        "Advanced Melanoma",
        "Advanced Ovarian Carcinoma",
        "Advanced Primary Peritoneal Carcinoma",
        "Advanced Synovial Sarcoma",
        "Clinical Stage III Cutaneous Melanoma AJCC v8",
        "Clinical Stage IV Cutaneous Melanoma AJCC v8",
        "Metastatic Fallopian Tube Carcinoma",
        "Metastatic Melanoma",
        "Metastatic Ovarian Carcinoma",
        "Metastatic Primary Peritoneal Carcinoma",
        "Metastatic Synovial Sarcoma",
        "Pathologic Stage III Cutaneous Melanoma AJCC v8",
        "Pathologic Stage IIIA Cutaneous Melanoma AJCC v8",
        "Pathologic Stage IIIB Cutaneous Melanoma AJCC v8",
        "Pathologic Stage IIIC Cutaneous Melanoma AJCC v8",
        "Pathologic Stage IIID Cutaneous Melanoma AJCC v8",
        "Pathologic Stage IV Cutaneous Melanoma AJCC v8",
        "Platinum-Resistant Fallopian Tube Carcinoma",
        "Platinum-Resistant Ovarian Carcinoma",
        "Platinum-Resistant Primary Peritoneal Carcinoma",
        "Stage III Fallopian Tube Cancer AJCC v8",
        "Stage III Ovarian Cancer AJCC v8",
        "Stage III Primary Peritoneal Cancer AJCC v8",
        "Stage IIIA Fallopian Tube Cancer AJCC v8",
        "Stage IIIA Ovarian Cancer AJCC v8",
        "Stage IIIA Primary Peritoneal Cancer AJCC v8",
        "Stage IIIA1 Fallopian Tube Cancer AJCC v8",
        "Stage IIIA1 Ovarian Cancer AJCC v8",
        "Stage IIIA2 Fallopian Tube Cancer AJCC v8",
        "Stage IIIA2 Ovarian Cancer AJCC v8",
        "Stage IIIB Fallopian Tube Cancer AJCC v8",
        "Stage IIIB Ovarian Cancer AJCC v8",
        "Stage IIIB Primary Peritoneal Cancer AJCC v8",
        "Stage IIIC Fallopian Tube Cancer AJCC v8",
        "Stage IIIC Ovarian Cancer AJCC v8",
        "Stage IIIC Primary Peritoneal Cancer AJCC v8",
        "Stage IV Fallopian Tube Cancer AJCC v8",
        "Stage IV Ovarian Cancer AJCC v8",
        "Stage IV Primary Peritoneal Cancer AJCC v8",
        "Stage IVA Fallopian Tube Cancer AJCC v8",
        "Stage IVA Ovarian Cancer AJCC v8",
        "Stage IVA Primary Peritoneal Cancer AJCC v8",
        "Stage IVB Fallopian Tube Cancer AJCC v8",
        "Stage IVB Ovarian Cancer AJCC v8",
        "Stage IVB Primary Peritoneal Cancer AJCC v8",
        "Unresectable Melanoma",
        "Unresectable Ovarian Carcinoma",
        "Unresectable Synovial Sarcoma"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Decitabine",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Leukapheresis",
          "type": "PROCEDURE"
        },
        {
          "name": "TGFbDNRII-transduced Autologous Tumor Infiltrating Lymphocytes",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "PROCEDURE",
        "BIOLOGICAL"
      ],
      "sponsor": "Roswell Park Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2017-07-14",
      "completion_date": "2032-07-14",
      "has_results": true,
      "last_update_posted_date": "2026-07-08",
      "last_synced_at": "2026-10-21T22:20:48.411Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02650986"
    },
    {
      "nct_id": "NCT01540474",
      "title": "Trial of a Falciparum Malaria Protein (FMP012), E. Coli-expressed PfCelTOS, in Healthy Malaria-Naive Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Malaria"
      ],
      "interventions": [
        {
          "name": "Group 1: 10 ug FMP012 with 2 ug GLA-SE",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Group 2: 10 ug FMP012 with 5 ug GLA-SE",
          "type": "BIOLOGICAL"
        },
        {
          "name": "50 ug FMP012 with 5 ug GLA-SE or 2 ug GLA-SE",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Controlled group-Challenged Only: no vaccination",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "U.S. Army Medical Research and Development Command",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 36,
      "start_date": "2012-02",
      "completion_date": "2012-12",
      "has_results": true,
      "last_update_posted_date": "2021-06-08",
      "last_synced_at": "2026-10-21T22:20:48.411Z",
      "location_count": 1,
      "location_summary": "Silver Spring, Maryland",
      "locations": [
        {
          "city": "Silver Spring",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01540474"
    },
    {
      "nct_id": "NCT00693654",
      "title": "Comparative Study of the Efficacy of SARNA Sensitive Lotion for Treatment of Uremic Itch in Adult Hemodialysis Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Pruritis"
      ],
      "interventions": [
        {
          "name": "Sarna",
          "type": "DRUG"
        },
        {
          "name": "Cetaphil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Wake Forest University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 28,
      "start_date": "2006-11",
      "completion_date": "2008-10",
      "has_results": true,
      "last_update_posted_date": "2018-09-10",
      "last_synced_at": "2026-10-21T22:20:48.411Z",
      "location_count": 1,
      "location_summary": "Winston-Salem, North Carolina",
      "locations": [
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00693654"
    },
    {
      "nct_id": "NCT00829595",
      "title": "Pneumococcal Vaccination in Patients With Inflammatory Bowel Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Inflammatory Bowel Disease",
        "Crohn Disease",
        "Ulcerative Colitis"
      ],
      "interventions": [
        {
          "name": "23-valent polysaccharide pneumococcal vaccine (Pneumovax TM)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Cedars-Sinai Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 69,
      "start_date": "2005-05",
      "completion_date": "2007-12",
      "has_results": false,
      "last_update_posted_date": "2009-01-27",
      "last_synced_at": "2026-10-21T22:20:48.411Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00829595"
    }
  ]
}